Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

CYLD is a causative gene for frontotemporal dementia - amyotrophic lateral sclerosis.

Carol Dobson-Stone | Marianne Hallupp | Hamideh Shahheydari | Audrey M G Ragagnin | Zac Chatterton | Francine Carew-Jones | Claire E Shepherd | Holly Stefen | Esmeralda Paric | Thomas Fath | Elizabeth M Thompson | Peter Blumbergs | Cathy L Short | Colin D Field | Peter K Panegyres | Jane Hecker | Garth Nicholson | Alex D Shaw | Janice M Fullerton | Agnes A Luty | Peter R Schofield | William S Brooks | Neil Rajan | Mark F Bennett | Melanie Bahlo | John E Landers | Olivier Piguet | John R Hodges | Glenda M Halliday | Simon D Topp | Bradley N Smith | Christopher E Shaw | Emily McCann | Jennifer A Fifita | Kelly L Williams | Julie D Atkin | Ian P Blair | John B Kwok
Brain : a journal of neurology | 2020

Frontotemporal dementia and amyotrophic lateral sclerosis are clinically and pathologically overlapping disorders with shared genetic causes. We previously identified a disease locus on chromosome 16p12.1-q12.2 with genome-wide significant linkage in a large European Australian family with autosomal dominant inheritance of frontotemporal dementia and amyotrophic lateral sclerosis and no mutation in known amyotrophic lateral sclerosis or dementia genes. Here we demonstrate the segregation of a novel missense variant in CYLD (c.2155A>G, p.M719V) within the linkage region as the genetic cause of disease in this family. Immunohistochemical analysis of brain tissue from two CYLD p.M719V mutation carriers showed widespread glial CYLD immunoreactivity. Primary mouse neurons transfected with CYLDM719V exhibited increased cytoplasmic localization of TDP-43 and shortened axons. CYLD encodes a lysine 63 deubiquitinase and CYLD cutaneous syndrome, a skin tumour disorder, is caused by mutations that lead to reduced deubiquitinase activity. In contrast with CYLD cutaneous syndrome-causative mutations, CYLDM719V exhibited significantly increased lysine 63 deubiquitinase activity relative to the wild-type enzyme (paired Wilcoxon signed-rank test P = 0.005). Overexpression of CYLDM719V in HEK293 cells led to more potent inhibition of the cell signalling molecule NF-κB and impairment of autophagosome fusion to lysosomes, a key process in autophagy. Although CYLD mutations appear to be rare, CYLD's interaction with at least three other proteins encoded by frontotemporal dementia and/or amyotrophic lateral sclerosis genes (TBK1, OPTN and SQSTM1) suggests that it may play a central role in the pathogenesis of these disorders. Mutations in several frontotemporal dementia and amyotrophic lateral sclerosis genes, including TBK1, OPTN and SQSTM1, result in a loss of autophagy function. We show here that increased CYLD activity also reduces autophagy function, highlighting the importance of autophagy regulation in the pathogenesis of frontotemporal dementia and amyotrophic lateral sclerosis.

Pubmed ID: 32185393

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: Wellcome Trust, United Kingdom
    Id: 100935/Z/13/Z
  • Agency: Wellcome Trust, United Kingdom
    Id: WT097163MA
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS073873
  • Agency: Motor Neurone Disease Association, United Kingdom
    Id: SMITH/APR16/847-791
  • Agency: Wellcome Trust, United Kingdom
  • Agency: MRF_, United Kingdom
    Id: MRF-060-0003-RG-SMITH
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS065847
  • Agency: Department of Health [UK], International

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.